AAPL 212.78 -1.1429% MSFT 386.0 -0.4693% NVDA 118.159 0.5437% GOOGL 162.26 -0.9946% GOOG 164.29 -1.1968% AMZN 194.215 -0.6776% META 590.9 1.1711% AVGO 189.5096 -3.0988% LLY 839.62 0.3118% TSLA 233.08 -1.1787% TSM 177.34 2.0603% V 339.53 -0.1% JPM 239.365 0.1066% UNH 510.88 1.5262% NVO 78.63 -0.4684% WMT 85.915 -0.4807% LVMUY 130.5 -2.1152% XOM 115.85 0.3812% LVMHF 655.0 -2.1687% MA 536.55 0.0858%
AAPL 212.78 -1.1429% MSFT 386.0 -0.4693% NVDA 118.159 0.5437% GOOGL 162.26 -0.9946% GOOG 164.29 -1.1968% AMZN 194.215 -0.6776% META 590.9 1.1711% AVGO 189.5096 -3.0988% LLY 839.62 0.3118% TSLA 233.08 -1.1787% TSM 177.34 2.0603% V 339.53 -0.1% JPM 239.365 0.1066% UNH 510.88 1.5262% NVO 78.63 -0.4684% WMT 85.915 -0.4807% LVMUY 130.5 -2.1152% XOM 115.85 0.3812% LVMHF 655.0 -2.1687% MA 536.55 0.0858%

small-cap

Technical Analysis on One NASDAQ- Listed Biotechnology Stock- RGC

Mar 18, 2025 | Team Kalkine
Technical Analysis on One NASDAQ- Listed Biotechnology Stock- RGC
Image source: shutterstock

RGC:NASDAQ
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)

Regencell Bioscience Holdings Ltd (NASDAQ: RGC)

Regencell Bioscience Holdings Ltd (NASDAQ: RGC) is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). 

Technical Observation (on the daily chart): 

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.